FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194531383> ?p ?o ?g. }

• W3194531383 endingPage "e829" @default.
• W3194531383 startingPage "e829" @default.
• W3194531383 abstract "Readers are invited to submit letters for publication in this department. Submit letters online at http://joem.edmgr.com. Choose “Submit New Manuscript.” A signed copyright assignment and financial disclosure form must be submitted with the letter. Form available at www.joem.org under Author and Reviewer information. To the Editor: We read with interest the article by Iddins et al.,1 reporting the immune response anti-SARS-CoV-2 IgG against the receptor binding domain (RBD) spike protein in healthcare workers. Since the risk of infection and poor outcomes seem also largely dependent on efficient anti-SARS-CoV-2 IgA response, assessing this antibody class is pivotal.2 Thus, we analyzed serum levels of total anti-spike RBD Ig, (Elecsys Anti-SARS-CoV-2S immunoassay on Roche Cobas 6000; Roche Diagnostics, Basel, Switzerland), anti-spike RBD IgG (ACCESS SARS-CoV-2 IgG II on Access 2; Beckman Coulter, Brea CA), and anti-spike S1 subunit IgA (Anti-SARS-CoV-2 ELISA IgA, manual ELISA; Euroimmun, Lübeck, Germany), in 24 healthcare workers undergoing vaccination with BNT162b2 mRNA COVID-19 at Peschiera del Garda hospital (Italy). This cohort comprised two matched samples of 12 baseline SARS-CoV-2 seronegative subjects (median age 40 years, interquartile range 31–52 years; 6 women) and 12 baseline SARS-CoV-2 seropositive subjects (median age 41 years, interquartile range 31–52 years; 6 women). Serum samples were drawn before the first vaccine dose, at 21 days (before the second vaccine dose) and 50 days afterwards. The study was conducted in accordance with the Helsinki Declaration and cleared by the Ethics Committee of Verona and Rovigo Provinces (3246CESC). The results are summarized in Table 1. Levels of all antibodies increased in both baseline SASR-CoV-2 seronegative and seropositive cohorts, though such increase continued after the second dose in baseline seronegative subjects, while reached a plateau in baseline seropositive subjects. In agreement with earlier data published by Vicenti et al,3 anti-SARS-CoV-2 RBD IgG levels after the first dose in baseline seropositive subjects were comparable to those achieved after two doses in baseline seronegative subjects (340.4 vs. 341.2 AU/mL; P = 0.259), while those of anti-SARS-CoV-2 RBD Total Ig (20,585.5 vs. 1629.0 AU/mL; P < 0.001) and anti-SARS-CoV-2 S1 Ig A (8.97 vs. 5.76 ratio; P < 0.001) were significantly higher. After the second dose, levels of anti-SARS-CoV-2 RBD Total Ig and Anti-SARS-CoV-2 S1 Ig A were still significantly higher in baseline seropositive subjects than in the seronegative cohort (both P < 0.001), while anti-SARS-CoV-2 RBD IgG levels were comparable (P = 0.068). TABLE 1 - Serum Levels of anti-SARS-CoV-2 Antibodies (Median and Interquartile Range) in Baseline SARS-CoV-2 Seronegative and Seropositive Healthcare Workers, Undergoing BNT162b2 mRNA COVID-19 Vaccination Baseline 21 days 50 days Antibodies Seronegative Seropositive P ∗ Seronegative Seropositive P ∗ Seronegative Seropositive P ∗ Anti-SARS-CoV-2 RBD Total Ig (AU/mL) 0.4 (0.4–0.4) 92.5 (15.9–141.5) <0.001 57.2 (21.2–98.0) 20,585.5 (11,902.0–24,527.5) <0.001 1629.0 (1136.3–2587.0) 19,984.0 (14,394.8–25,000.0) <0.001 Anti-SARS-CoV-2 RBD IgG (AU/mL) 0.2 (0.1–0.2) 10.0 (8.0–14.4) <0.001 41.7 (23.1–88.1) 340.4 (241.8–433.2) <0.001 341.2 (263.7–641.2) 306.4 (262.7–358.2) 0.068 Anti-SARS-CoV-2 S1 IgA (ratio) 0.23 (0.16–0.31) 1.17 (0.78–1.70) <0.001 3.15 (2.02–5.65) 8.97 (8.79–10.41) <0.001 5.76 (3.67–7.28) 8.76 (8.01–9.75) <0.001 Ig, immunoglobulin; RBD, receptor binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.∗Seropositive vs. seronegative. Our results, reporting anti-SARS-CoV-2 IgA antibodies response after BNT162b2 mRNA COVID-19 vaccination, suggest that consideration could be given to delay and/or omit the second vaccine dose in baseline SARS-CoV-2 seropositive subjects." @default.
• W3194531383 created "2021-08-30" @default.
• W3194531383 creator A5039747681 @default.
• W3194531383 creator A5068599898 @default.
• W3194531383 creator A5073522064 @default.
• W3194531383 date "2021-08-17" @default.
• W3194531383 modified "2023-10-10" @default.
• W3194531383 title "Anti-SARS-CoV-2 IgA Response in Baseline Seronegative and Seropositive Recipients of BNT162b2 mRNA COVID-19 Vaccine" @default.
• W3194531383 cites W3139354691 @default.
• W3194531383 cites W3140400537 @default.
• W3194531383 cites W3161156876 @default.
• W3194531383 doi "https://doi.org/10.1097/jom.0000000000002362" @default.
• W3194531383 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8562910" @default.
• W3194531383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34412098" @default.
• W3194531383 hasPublicationYear "2021" @default.
• W3194531383 type Work @default.
• W3194531383 sameAs 3194531383 @default.
• W3194531383 citedByCount "1" @default.
• W3194531383 countsByYear W31945313832022 @default.
• W3194531383 crossrefType "journal-article" @default.
• W3194531383 hasAuthorship W3194531383A5039747681 @default.
• W3194531383 hasAuthorship W3194531383A5068599898 @default.
• W3194531383 hasAuthorship W3194531383A5073522064 @default.
• W3194531383 hasBestOaLocation W31945313831 @default.
• W3194531383 hasConcept C119060515 @default.
• W3194531383 hasConcept C126322002 @default.
• W3194531383 hasConcept C159047783 @default.
• W3194531383 hasConcept C159654299 @default.
• W3194531383 hasConcept C203014093 @default.
• W3194531383 hasConcept C2779134260 @default.
• W3194531383 hasConcept C2909509916 @default.
• W3194531383 hasConcept C3007834351 @default.
• W3194531383 hasConcept C3008058167 @default.
• W3194531383 hasConcept C524204448 @default.
• W3194531383 hasConcept C71924100 @default.
• W3194531383 hasConcept C72563966 @default.
• W3194531383 hasConceptScore W3194531383C119060515 @default.
• W3194531383 hasConceptScore W3194531383C126322002 @default.
• W3194531383 hasConceptScore W3194531383C159047783 @default.
• W3194531383 hasConceptScore W3194531383C159654299 @default.
• W3194531383 hasConceptScore W3194531383C203014093 @default.
• W3194531383 hasConceptScore W3194531383C2779134260 @default.
• W3194531383 hasConceptScore W3194531383C2909509916 @default.
• W3194531383 hasConceptScore W3194531383C3007834351 @default.
• W3194531383 hasConceptScore W3194531383C3008058167 @default.
• W3194531383 hasConceptScore W3194531383C524204448 @default.
• W3194531383 hasConceptScore W3194531383C71924100 @default.
• W3194531383 hasConceptScore W3194531383C72563966 @default.
• W3194531383 hasIssue "11" @default.
• W3194531383 hasLocation W31945313831 @default.
• W3194531383 hasLocation W31945313832 @default.
• W3194531383 hasLocation W31945313833 @default.
• W3194531383 hasLocation W31945313834 @default.
• W3194531383 hasLocation W31945313835 @default.
• W3194531383 hasOpenAccess W3194531383 @default.
• W3194531383 hasPrimaryLocation W31945313831 @default.
• W3194531383 hasRelatedWork W2061253854 @default.
• W3194531383 hasRelatedWork W3034816694 @default.
• W3194531383 hasRelatedWork W3036305013 @default.
• W3194531383 hasRelatedWork W3127693599 @default.
• W3194531383 hasRelatedWork W3127981252 @default.
• W3194531383 hasRelatedWork W4205317059 @default.
• W3194531383 hasRelatedWork W4206669628 @default.
• W3194531383 hasRelatedWork W4210401150 @default.
• W3194531383 hasRelatedWork W4211073736 @default.
• W3194531383 hasRelatedWork W4385264226 @default.
• W3194531383 hasVolume "63" @default.
• W3194531383 isParatext "false" @default.
• W3194531383 isRetracted "false" @default.
• W3194531383 magId "3194531383" @default.
• W3194531383 workType "article" @default.